RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 125 filers reported holding RA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $52,660,000 | +590.7% | 1,096,869 | +575.2% | 0.04% | +950.0% |
| Q4 2019 | $7,624,000 | +1575.6% | 162,443 | +744.9% | 0.00% | – |
| Q3 2019 | $455,000 | -69.7% | 19,226 | -61.5% | 0.00% | -100.0% |
| Q2 2019 | $1,502,000 | +135.8% | 49,959 | +75.8% | 0.00% | – |
| Q1 2019 | $637,000 | +57.3% | 28,411 | +27.6% | 0.00% | – |
| Q4 2018 | $405,000 | -19.3% | 22,263 | -19.7% | 0.00% | – |
| Q3 2018 | $502,000 | +924.5% | 27,742 | +450.9% | 0.00% | – |
| Q2 2018 | $49,000 | +22.5% | 5,036 | -33.2% | 0.00% | – |
| Q1 2018 | $40,000 | -21.6% | 7,534 | +27.0% | 0.00% | – |
| Q4 2017 | $51,000 | -65.8% | 5,932 | -41.7% | 0.00% | – |
| Q3 2017 | $149,000 | +28.4% | 10,177 | +64.5% | 0.00% | – |
| Q2 2017 | $116,000 | +61.1% | 6,185 | +83.5% | 0.00% | – |
| Q1 2017 | $72,000 | +38.5% | 3,370 | -3.1% | 0.00% | – |
| Q4 2016 | $52,000 | – | 3,479 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |